A fairly quiet week on the deal front, but if Becton Dickinson can sell $750 million of 10- and 30-year notes just for the heck of it, things in the market can’t be too bad, right? Here’s what I saw on the wires this week…
Public Offering:
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) closed the full amount and the full over-allotment of its unit offering that we noted a couple of weeks ago at launch, for gross proceeds of $6.9 million.
New NRC-BRI Project:
DNP Green Technology announced a scientific agreement with the National Research Council of Canada Biotechnology Research Institute (NRC-BRI). This partnership aims to develop a second-generation technology for the production of bio-based succinic acid, which is used in various industrial applications. DNP Green Technology and Agro-Industrie Recherches et Développements (ARD) have a joint venture, Bioamber, which has already developed a first-generation technology for producing bio-based succinic acid, which it expects to begin licensing in the coming year.
Funding with Strings Attached:
Akela Pharma Inc. (TSX: AKL) is recording a charge based on a demand by Tekes, the Finnish Funding Agency for Technology and Innovation, for repayment of certain grants obtained by Akela in 2004 and 2005 totaling US$1,544,000. Following Akela’s decision to down-size its Finnish operations in the summer of 2007, Tekes made a demand for repayment of the grants, together with interest. The loans remain outstanding on the original repayment schedule.
Nice to hear this. Money matters always. This site might also be helpful. Thanks.
Pingback: Monday Deal Review: July 6, 2009 « The Cross-Border Biotech Blog